🇺🇸 FDA
Pipeline program

FMX114

VY2021-01

Phase 2 small_molecule completed

Quick answer

FMX114 for Atopic Dermatitis is a Phase 2 program (small_molecule) at VYNE Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
VYNE Therapeutics
Indication
Atopic Dermatitis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials